These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25399822)

  • 1. Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial.
    Galadanci NA; Abdullahi SU; Tabari MA; Abubakar S; Belonwu R; Salihu A; Neville K; Kirkham F; Inusa B; Shyr Y; Phillips S; Kassim AA; Jordan LC; Aliyu MH; Covert BV; DeBaun MR
    Pediatr Blood Cancer; 2015 Mar; 62(3):395-401. PubMed ID: 25399822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
    Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
    Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annual stroke incidence in Nigerian children with sickle cell disease and elevated TCD velocities treated with hydroxyurea.
    Lagunju I; Brown BJ; Oyinlade AO; Asinobi A; Ibeh J; Esione A; Sodeinde OO
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27252. PubMed ID: 29797633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia.
    Zimmerman SA; Schultz WH; Burgett S; Mortier NA; Ware RE
    Blood; 2007 Aug; 110(3):1043-7. PubMed ID: 17429008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort.
    Lagunju I; Brown BJ; Sodeinde O
    Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
    Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
    Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of hydroxyurea in prevention of stroke in children with sickle cell disease.
    Lefèvre N; Dufour D; Gulbis B; Lê PQ; Heijmans C; Ferster A
    Blood; 2008 Jan; 111(2):963-4; author reply 964. PubMed ID: 18182580
    [No Abstract]   [Full Text] [Related]  

  • 8. Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.
    Abdullahi SU; DeBaun MR; Jordan LC; Rodeghier M; Galadanci NA
    Pediatr Neurol; 2019 Jun; 95():73-78. PubMed ID: 30952488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcranial Doppler screening in Nigerian children with sickle cell disease: A 10-year longitudinal study on the SPPIBA cohort.
    Lagunju IA; Labaeka A; Ibeh JN; Orimadegun AE; Brown BJ; Sodeinde OO
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28906. PubMed ID: 33522690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
    Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
    Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
    Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
    Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.
    Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ
    Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
    N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing Sickle Cell Disease Stroke Prevention Teams in Africa is Feasible: Program Evaluation Using the RE-AIM Framework.
    Ghafuri DL; Abdullahi SU; Dambatta AH; Galadanci J; Tabari MA; Bello-Manga H; Idris N; Inuwa H; Tijjani A; Suleiman AA; Jibir BW; Gambo S; Gambo AI; Khalifa Y; Haliru L; Abdulrasheed S; Zakari MA; Greene BC; Trevathan E; Jordan LC; Aliyu MH; Baumann AA; DeBaun MR
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e56-e61. PubMed ID: 34001783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial.
    Hankins JS; McCarville MB; Rankine-Mullings A; Reid ME; Lobo CL; Moura PG; Ali S; Soares DP; Aldred K; Jay DW; Aygun B; Bennett J; Kang G; Goldsmith JC; Smeltzer MP; Boyett JM; Ware RE
    Am J Hematol; 2015 Dec; 90(12):1099-105. PubMed ID: 26414435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
    Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial.
    Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
    Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team.
    Bello-Manga H; Haliru L; Tabari AM; Farouk B; Suleiman A; Bahago GY; Sani AM; Bauman AA; DeBaun MR; King AA
    BMC Res Notes; 2022 Jan; 15(1):1. PubMed ID: 34983646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
    Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approximately 40 000 children with sickle cell anemia require screening with TCD and treating with hydroxyurea for stroke prevention in three states in northern Nigeria.
    Galadanci AA; Galadanci NA; Jibir BW; Abdullahi SU; Idris N; Gambo S; Ali Abubakar SA; Kabo NA; Bello-Manga H; Haliru L; Bashir I; Aliyu MH; Galadanci JA; DeBaun MR
    Am J Hematol; 2019 Nov; 94(11):E305-E307. PubMed ID: 31423630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.